Abstract 6074
Background
In Spain, we do not have real-time information about cancer survivors follow-up by their family doctor. The main objective of this study is to describe the characteristics and quality of life of cancer survivors followed at a primary care center in Northwest of Spain.
Methods
An individual interview was conducted with 100 survivors of breast or colon or lung cancer, all of them free of disease five or more years after their initial diagnosis. Socio-demographic variables, care plan and global quality of life assessment (using the EORTC QLQ-C30 questionnaire), were collected.
Results
We analyzed socio-demographic data of 72 women and 28 men. At the time of the interview, their median age was 66-years-old (37-99), most were married (61%), had primary studies (58%) and do not work (77 %). We analyzed aspects related to their global quality of life by using the EORTC QLQ-C30 questionnaire. A third (36%), acknowledged that their cancer diagnosis had influenced their employment status. More than 50% of survivors recognized asthenia and/or pain at the time of the interview, and at least a 15% and 20% of these cases respectively, related these symptoms to their previous diagnosis of cancer. More than a half (56%) acknowledged their previous cancer diagnosis had changed their lifes, and to a lesser extent the life of their family (28%) and economy. A 64% of the interviewed survivors considered that their enjoyed a good or a very good quality of life. Most ot the cancer survivors (75%) described themselves as cured people.
Conclusions
Most survivors recognized that their cancer diagnosis changed their lives, and up to a third of the cases also their work situation. However, the majority of survivors report a globally good quality of life and describe themselves as cured people.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Begoña Graña.
Funding
SEOM - "Oncovida" scholarship.
Disclosure
B. Grana Suarez: Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Celgene; Research grant / Funding (institution): Roche; Travel / Accommodation / Expenses: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract